Oxford Biomedica Reports Improved First-Half Performance and Maintains Revenue Guidance
Oxford Biomedica reported a strong first-half performance in fiscal year 2026, with revenue rising by 10% to £80.2 million at constant currency, driven primarily by a 20% increase in manufacturing revenue. The company narrowed its adjusted EBITDA loss to £2.5 million and maintained full-year guidance of £180–£200 million in revenue for the year ahead. The firm also highlighted growing demand, with new client signings increasing active programs from 44 a year ago to 60 by September 2026. Revenue backlog expanded significantly to £299 million as of August and its commercial pipeline reached $730 million at mid-year — up 30% year-over-year. Management reiterated long-term goals, including reaching approximately £500 million in revenue by 2030. Oxford Biomedica’s CEO noted a shift toward more diversified opportunities across vector types and geographies, with AAV programs surpassing lentiviral ones for the first time. The U.S. now accounts for 40% of pipeline value — up from 24% in the prior year.
Topics: biotech guidance maintenance manufacturing revenue growth